A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
BP43131
Phase 1 other active
Quick answer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL) is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)
- Phase
- Phase 1
- Modality
- other
- Status
- active